Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

OASIS Optimal Methods to Characterize Adc Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Coordinator
Institut Gustave Roussy, France
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€9.9m
Total cost
—
Partners
13 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101156771

What the project is doing

In the project's own words, from its summary on CORDIS.

Over the past 5 years, antibody drug conjugates (ADCs) have shown impressive improvements in survival outcomes of solid tumors and hematological malignancies. With 14 ADCs already approved across different countries and more than 140 that entered the clinical development, they are intended to replace standard chemotherapies across multiple tumor types over the next decade. Although ADCs show great clinical efficacy, resistance eventually occurs, and it becomes critical to understand resistance mechanisms to guide the choice of the following lines of therapy for patients who progress on a given ADC.

Given the complex nature of ADCs, immunocompromised mouse models (nude mice, NOD-SCID or NOG mice) and currently used clinical assays (standard radiology, IHC, WES etc) are not the optimal preclinical and clinical tools, to identify the multiple causes of resistance. The OASIS project aims to generate a biobank of different patient-derived organoids (PDOs), which better recapitulate ADCs resistance and integrate different assays, spanning from whole-body molecular imaging (Ab-radiolabeled PET scan or immunoPET), circulating tumor cells (CTC), plasma proteomics, to multiplex immunofluorescence (MIF) and machine-learning enhanced digital pathology (AI-digital pathology) to capture most of the parallel mechanisms of resistance to ADCs.

Such tools will enable to define biomarkers of ADC resistance that can inform further therapeutic decisions.

Topics

Who is involved

OrganisationCityCountryRole
Institut Gustave RoussyVillejuifFranceCoordinator
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumParticipant
Cancer Patients EuropeBruxelles / BrusselBelgiumParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Panepistimio KritisRethimnoGreeceParticipant
CentralesupelecGif Sur YvetteFranceParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Elikya Therapeutics SASStrasbourgFranceParticipant
Gustave Roussy TransfertVillejuifFranceThird party
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Orakl Oncology SASLe Kremlin-BicetreFranceParticipant
UnicancerParisFranceParticipant
Olink Proteomics ABUppsalaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI